Vitura Health Yönetim

Yönetim kriter kontrolleri 2/4

Vitura Health CEO'su Tom Howitt, Apr2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı A$ 438.54K olup, şirket hissesi ve opsiyonları dahil olmak üzere 89% maaş ve 11% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.21% ine doğrudan sahiptir ve bu hisseler A$ 118.78K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 1.5 yıldır.

Anahtar bilgiler

Tom Howitt

İcra Kurulu Başkanı

AU$438.5k

Toplam tazminat

CEO maaş yüzdesi	89.0%
CEO görev süresi	less than a year
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.5yrs

Son yönetim güncellemeleri

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Nov 21

Recent updates

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Oct 17

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Oct 13

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Sep 07

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Aug 12

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Aug 12

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

Apr 25

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Apr 11

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Feb 27

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Feb 25

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Dec 13

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Nov 21

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Nov 01

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Jul 18

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Sep 12

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Sep 05

CEO Tazminat Analizi

Tom Howitt'un ücretlendirmesi Vitura Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$439k	AU$390k	AU$4m
Mar 31 2024	n/a	n/a	AU$6m
Dec 31 2023	n/a	n/a	AU$9m
Sep 30 2023	n/a	n/a	AU$12m
Jun 30 2023	AU$669k	AU$320k	AU$14m
Mar 31 2023	n/a	n/a	AU$12m
Dec 31 2022	n/a	n/a	AU$10m
Sep 30 2022	n/a	n/a	AU$8m
Jun 30 2022	AU$818k	AU$307k	AU$6m
Mar 31 2022	n/a	n/a	AU$5m
Dec 31 2021	n/a	n/a	AU$5m
Sep 30 2021	n/a	n/a	AU$3m
Jun 30 2021	AU$429k	AU$307k	AU$1m
Mar 31 2021	n/a	n/a	-AU$194k
Dec 31 2020	n/a	n/a	-AU$2m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$443k	AU$307k	-AU$4m
Mar 31 2020	n/a	n/a	-AU$4m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$354k	AU$175k	-AU$3m

Tazminat ve Piyasa: Tom 'ın toplam tazminatı ($USD 285.15K ) Australian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 297.81K ).

Tazminat ve Kazançlar: Tom 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Tom Howitt (60 yo)

less than a year

Görev süresi

AU$438,538

Tazminat

Mr. Thomas Godfrey Howitt, also known as Tom, BCom, CA, FTIA, ACIS, AICPA, is Interim Chief Executive Officer of Vitura Health Limited (formerly known as Cronos Australia Limited) since April 22, 2024 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Howitt	Interim Chief Executive Officer	less than a year	AU$438.54k	0.21% A$ 118.8k
Ben Cirillo	Interim Chief Financial Officer	less than a year	AU$58.07k	0.025% A$ 14.0k
Ryan Tattle	Chief Revenue Officer	1.8yrs	AU$362.46k	0.60% A$ 341.6k
Nicola Swarbrick	Chief Operating Officer	less than a year	Veri yok	Veri yok
Stefan Schmidt	Chief Technology Officer	less than a year	Veri yok	Veri yok
Erin Leckie	Interim Head of Marketing	3.4yrs	Veri yok	Veri yok
Deanna Johns	Head of People & Culture	2.8yrs	Veri yok	Veri yok
Jeffrey Lerner	Head of Technology	1.4yrs	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: VIT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Iervasi	Independent Non-Executive Chairman	less than a year	AU$67.83k	0.080% A$ 45.5k
Guy Headley	Non-Executive Director	less than a year	AU$409.40k	17.27% A$ 9.8m
Marcia Ani Walker	Independent Non-Executive Director	2.9yrs	AU$71.92k	Veri yok
Jenelle Frewen	Independent Non-Executive Director	2.2yrs	AU$55.50k	0.033% A$ 18.9k

1.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: VIT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Vitura Health Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vitura Health Limited Announces Step Down of Directors

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Vitura Health Limited, Annual General Meeting, Nov 27, 2024

Less than half of directors are independent

Board Member recently sold AU$1.1m worth of stock

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Recent updates

Crisci Group and Vitura Health Limited (ASX:VIT) acquired Assets of Releaf Group from Releaf Group Ltd for AUD 6.07 million .

Vitura Health Limited Announces Step Down of Directors

Now 22% undervalued

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Vitura Health Limited, Annual General Meeting, Nov 27, 2024

Full year 2024 earnings released: EPS: AU$0.006 (vs AU$0.025 in FY 2023)

Vitura Health Limited Resolves Not to Pay A Dividend in Respect of the Year Ended 30 June 2024

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Less than half of directors are independent

Board Member recently sold AU$1.1m worth of stock

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

New major risk - Share price stability

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Now 39% undervalued after recent price drop

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Vitura Health Limited Receives Shareholder Requisition from Elizabeth Sarah Jansen

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Vitura Health Limited (ASX:VIT) completed the acquisition of acquire an unknown stake in Doctors on Demand from Yeates Ventures Pty Ltd and Kirsty Garrett.

New minor risk - Shareholder dilution

Vitura Health Limited, Annual General Meeting, Nov 28, 2023

Upcoming dividend of AU$0.01 per share at 2.7% yield

Vitura Health Limited Announces Dividend for the Year Ended 30 June 2023, Payable on or Around, 28 September 2023

New major risk - Earnings quality

New minor risk - Financial data availability

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Insider recently sold AU$2.3m worth of stock

New minor risk - Share price stability

Chief Commercial Officer recently sold AU$5.9m worth of stock

High number of new and inexperienced directors

Cronos Australia Limited Announces Changes to Clinical Operations

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Ceases of Benjamin D.N. Jansen as Chief Medical Officer

Cronos Australia Limited Provides Update on Canview 2.0 Platform

Cronos Australia Limited, Annual General Meeting, Nov 29, 2022

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Cronos Australia Limited Appoints Jenelle Frewen and Simone Scovell as Independent Non-Executive Director

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Cronos Australia Limited Announces Dividend for the Year Ended 30 June 2022, Dividend Payment Date Is 11 October 2022

Full year 2022 earnings released: EPS: AU$0.013 (vs AU$0.031 loss in FY 2021)

Cronos Australia Limited to Report Q2, 2022 Results on Jul 27, 2022

Cronos Australia Announces Resignation of Shane Tanner, Chairman and Director

Cronos Australia Limited Announces Resignation of Kurt Thomas Schmidt as Director

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cronos Australia Limited (ASX:CAU) completed the acquisition of Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited (ASX:CAU) entered into Merger implementation agreement to acquire Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited Announces Launch of Additional Products in Key Asian Markets

Cronos Australia Limited Provides Revenue Guidance for the Fourth Quarter of 2021

Cronos Australia Limited Announces Launch of First Personal Care Brand in North Asian Markets with Bathing Shed

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi